alendronate has been researched along with Chronic Kidney Failure in 7 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We describe a case of collapsing focal segmental glomerulosclerosis and severe kidney dysfunction in a liver transplant recipient after the initiation of alendronate for osteopenia." | 7.74 | Collapsing focal segmental glomerulosclerosis in a liver transplant recipient on alendronate. ( Djamali, A; Musat, A; Myers, J; Pascual, J; Samaniego, M; Tome, S; Torrealba, J, 2007) |
| "We describe a case of collapsing focal segmental glomerulosclerosis and severe kidney dysfunction in a liver transplant recipient after the initiation of alendronate for osteopenia." | 3.74 | Collapsing focal segmental glomerulosclerosis in a liver transplant recipient on alendronate. ( Djamali, A; Musat, A; Myers, J; Pascual, J; Samaniego, M; Tome, S; Torrealba, J, 2007) |
| " We calculated the standard mean deviations with 95% confidence intervals (CI) for bone mineral density (BMD) and T scores after 6 and 12 months treatment, pooled odds ratio and 95% CI for fracture risk, and summarized adverse events." | 3.01 | Efficacy and safety of medications for osteoporosis in kidney transplant recipients or patients with chronic kidney disease: A meta-analysis. ( Leng, Y; Xia, Y; Yang, Y; Yu, X, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Leng, Y | 1 |
| Yu, X | 1 |
| Yang, Y | 1 |
| Xia, Y | 1 |
| Neves, JM | 1 |
| Cabete, J | 1 |
| Fernandes, C | 1 |
| Etemadi, J | 1 |
| Bagheri, N | 1 |
| Falaknazi, K | 1 |
| Ardalan, M | 1 |
| Rahbar, K | 1 |
| Nobakht Haghighi, A | 1 |
| Mohajel Shoja, M | 1 |
| Toussaint, ND | 1 |
| Lau, KK | 1 |
| Strauss, BJ | 1 |
| Polkinghorne, KR | 1 |
| Kerr, PG | 1 |
| Abediazar, S | 1 |
| Nakhjavani, MR | 1 |
| Pascual, J | 1 |
| Torrealba, J | 1 |
| Myers, J | 1 |
| Tome, S | 1 |
| Samaniego, M | 1 |
| Musat, A | 1 |
| Djamali, A | 1 |
| Yee, J | 1 |
1 review available for alendronate and Chronic Kidney Failure
| Article | Year |
|---|---|
Efficacy and safety of medications for osteoporosis in kidney transplant recipients or patients with chronic kidney disease: A meta-analysis.
Topics: Adult; Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Fractures, Bone; | 2023 |
1 trial available for alendronate and Chronic Kidney Failure
| Article | Year |
|---|---|
Effect of alendronate on vascular calcification in CKD stages 3 and 4: a pilot randomized controlled trial.
Topics: Aged; Alendronate; Aorta; Calcinosis; Female; Humans; Kidney; Kidney Failure, Chronic; Male; Middle | 2010 |
5 other studies available for alendronate and Chronic Kidney Failure
| Article | Year |
|---|---|
Nonuraemic cutaneous calciphylaxis: our experience with a challenging disease.
Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation | 2020 |
Paget's disease of bone in a patient on hemodialysis.
Topics: Aged; Alendronate; Alkaline Phosphatase; Bone Density Conservation Agents; Female; Humans; Kidney Fa | 2008 |
Effect of alendronate on early bone loss of renal transplant recipients.
Topics: Adult; Alendronate; Body Mass Index; Bone and Bones; Bone Density; Bone Density Conservation Agents; | 2011 |
Collapsing focal segmental glomerulosclerosis in a liver transplant recipient on alendronate.
Topics: Alendronate; Bone Density Conservation Agents; Bone Diseases, Metabolic; Glomerulosclerosis, Focal S | 2007 |
Chronic kidney disease--a disease domain complex.
Topics: Aged; Alendronate; Amlodipine; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Asp | 2008 |